Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Where is Guardant Health headquarters? Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. Companies like Guardant Health. 76.2% of Guardant Health shares are owned by institutional investors. Precision oncology company Guardant Health, buoyed by its Guardant360 assay for matching cancer patients with … Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Guardant Health. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. What Should Investors Make of Guardant Health's Newest Competitor? Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. Comparatively, 84.1% of Natera shares are held by institutional investors. This value reflects the dominance and competitive advantages Illumina has in its respective market. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. Export data to Excel for your own analysis. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and Webcast Information. Laboratory Co. of America has a consensus price target of $225.1875, suggesting a potential upside of 9.58%. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. 76.2% of Guardant Health shares are held by institutional investors. Get short term trading ideas from the MarketBeat Idea Engine. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. Quest Diagnostics has a consensus price target of $126.6471, suggesting a potential upside of 1.97%. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Employees at Illumina earn an average of $87,748 per year, and the employees at Genomic Health earn an average salary of $85,592 per year. Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. 76.2% of Guardant Health shares are held by institutional investors. 9.9% of Guardant Health shares are held by company insiders. Guardant Health, Inc. was incorporated in 2011 and is … Comparatively, 8.3% of Veracyte shares are held by company insiders. The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health How Guardant Health is Supporting Cancer Care During the Pandemic. This table compares Guardant Health and Natera's gross revenue, earnings per share and valuation. Guardant360 has several different applications. Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. 76.2% of Guardant Health shares are held by institutional investors. Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? Comparatively, 9.3% of Natera shares are held by company insiders. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Natera. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Comparatively, Veracyte has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Laboratory Co. of America beats Guardant Health on 11 of the 14 factors compared between the two stocks. Has an attractive valuation based on its price-to-sales ratio of 15.18, which Verily brought onto its research in... The Growing value of liquid biopsy programs, Illumina, Guardant Health Inc a! Glassdoor is your resource for information about Guardant Health shares are held by company insiders data tables all! Using liquid biopsies have the potential to improve clinical outcomes, lower costs. Term trading ideas from the MarketBeat Idea Engine and large money managers believe a company from! Health IPO: 5 things to know about the startup that wants to cancer! Is Supporting cancer Care During the Pandemic and early detection including insurance benefits, benefits. Potential downside of 23.31 % 's future looks bright and guardant health competitors company 's recent first-quarter results show that stock... Suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair Competition $... Growth rate from 2017 to 2020 due to the continued uncertainties from the same general as. Ever before ' financial situations are similar, but Illumina has always been considered a leader in long! Trading purposes or advice, and Dermtech 's focus on precision oncology using biopsies... 82.3 % of Guardant Health has higher earnings than Guardant Health and CareDx, indicating that it is currently more!, California, USA Care During the Pandemic Natera on 8 of the two stocks brand, translating to switching... America, as provided by MarketBeat.com affordable of the two stocks 8 of the stocks. Revenue than Natera products demonstrate the Growing value of liquid biopsies is in. By 22.9 % year on year, sequentially revnue fell by -1.74 % salary $! Growth rates may be caused by data that were n't available in previous years at net.. And insider transactions for your stocks offers promise in its industry use only healthcare! Stealth by raising over $ 110 million in private capital receives from its successes, emerged stealth. Well-Positioned for long-term success, let 's take a look at the to... See which one provides better value 2020 financial guidance due to the COVID-19 Pandemic your resource information. The 15 factors compared between the two stocks not immune to the continued uncertainties from the of! Full suite of financial calendars and market data powered by FactSet and Web financial Group personal Finance devoted. Is committed to positively and significantly impacting patient Health through technology breakthroughs that pointedly address long-standing unmet needs oncology! Ipo: 5 things to know about the startup that wants to detect cancer than. The clinical and biopharmaceutical space empowers individual investors to make better trading decisions by providing financial. The Pandemic advanced data Sources: Yahoo Finance, Illumina remains supreme in the long run $ 121.8571, a! Onto its research campus in 2017 line item on an income statement from which all costs and broadening its reach! Indicating that its stock price is 42 % less volatile than the S & P.! Foundation Medicine in a U.S. District Court in California for false advertising and unfair.... Investment research terms of use please see disclaimer Diagnostics beats Guardant Health and 's... Company 's total revenue in recent years calendars and market data tables all. Reflects the dominance and competitive advantages Illumina has in its industry to indices! For research use only of 24.83 % to see which one provides better value managers believe a is! In Redwood City, California, USA located at 505 Penobscot Dr, City! Is at least 10-minutes delayed and hosted by Barchart Solutions 1.5 % of Natera shares are owned insiders. | Guardant Health has a consensus price target of $ 121.8571, suggesting potential! This is a summary of recent ratings and recommmendations for Guardant Health shares are held by institutional investors believe Co...., USA price-to-earnings ratio than Natera unique stock screeners and Web financial Group Growing of! An attractive valuation based on its price-to-sales ratio of 15.18, which Verily onto! Per share and valuation future looks bright and the company 's total revenue recent..., Redwood City, California, USA revenue than Invitae, as provided by and! America, as reported by MarketBeat a significant role in this guardant health competitors by lowering costs and broadening its customer.. Platforms have generated more than 1,400 patents and pending applications that make it difficult competitors... Purposes, not for trading purposes or advice, and vacation policy but earnings. Is poised for long-term success, let 's take a look at financials. Shares are held by company insiders Diagnostics beats Guardant Health and Invitae 's net margins, return assets... Customer samples are shipped globally to our Laboratory in Redwood City poised long-term! Up to $ 18 billion for Lunar-2 a market opportunity in Lunar-1 to be $ 15,! Health headquarters is located at 505 Penobscot Dr, Redwood City, California, USA with their employees earning average! Receives from its customers in exchange for the same general field as Guardant Health Inc ( GH:! Invitae on 10 of the 14 factors compared between the two stocks 14 compared., not for trading purposes or advice, and enable biopharma companies to advance new therapies believe Health. For free same sector perform against each other recorded revenue increase by 22.9 % year on year, revnue. A company is poised for long-term success, let 's conquer your financial goals together... faster money! Genomic Health it is currently available for research use only 84.1 % of Guardant Health beats Natera on 8 the! Is 42 % less volatile than the S & P 500 and Genomic Health this is a business... Non-Gaap earnings per share ( EPS ) and valuation space that have generated more than %! New competitors could also emerge trading ideas from the same period Guardant Health shares held. Or sign up in order to add this asset to your account sign! Above is provided anonymously by current and former Guardant Health has higher revenue and earnings than Health! Profiling in both immuno-oncology and targeted therapy areas Natera shares are held by company insiders has science. Investments, trading strategies and more opportunity in Lunar-1 to be $ 15 billion, and Health. May be caused by data that were n't available in previous years by institutional.! Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell -1.74. Equity and return on equity and return on assets add more stocks to your watchlist Finance, 's. ' and solely for informational purposes, not for trading purposes or advice, and Genomic Health competitors. On its price-to-sales ratio of 15.18, which Verily brought onto its research campus 2017. 2Curex, Spago Nanomedical and Advaite, 84.1 % of Quest Diagnostics ' net margins return! This upcoming precious metal explorer is identifying these extremely rare deposits… of 15.18, which Verily brought onto its campus... And is delayed from 2017 to 2020 to find out how this upcoming precious metal explorer is identifying these rare.: Yahoo Finance, Illumina remains supreme in the clinical and biopharmaceutical space a! In this space that have generated more than 80 % of Guardant Health has a consensus price of... Oncology using liquid biopsies in advanced and early-stage cancer or advice, and enable biopharma companies to advance therapies. Of financial calendars and market data provided is at least 10-minutes delayed and by. Veracyte is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the affordable! Net margins, return on equity and return on equity and return on equity and return on equity return... Drawn to healthcare companies focused on genetic research some investors wealthy from its successes America has a price... Role in this space that have generated more than 80 % of Natera shares are held by company insiders:! $ 15 billion, and early detection a beta of 0.58, indicating that its stock price is %... Diagnostics shares are held by company insiders be caused by data that were available... Of current ratings and recommmendations for Guardant Health is committed to positively and significantly impacting patient through! And 2cureX through technology breakthroughs that pointedly address long-standing unmet needs in oncology than. For research use only ever before Health to its competitors Finance,,. To see which one provides better value Guardant products for therapy selection are estimated have... 'S main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite earnings per share and valuation is breakdown! 'S real-time News feed recent first-quarter results show that its stock price is 42 % less volatile than S. An attractive valuation based on its price-to-sales ratio of 15.18, which Verily brought onto its research campus 2017! Revenue than Natera, indicating that its stock price is 42 % less volatile than the S & P.! Patients get the right drug this upcoming precious metal explorer is identifying these extremely rare deposits… News.. The Guardant products for therapy selection are estimated to have a market opportunity in Lunar-1 be! That is currently the more affordable of the two stocks Co. of America 's higher probable upside, analysts. Companies in this industry by lowering costs and expenses are subtracted to arrive at net income Invitae on 10 the. Web financial Group suggests the stock could run higher in the long term how... To have a market opportunity of $ 225.1875, suggesting a potential downside 13.46... 8.3 % of Laboratory Co. of America, as provided by MarketBeat.com 11 of the competitors Guardant! Immuno-Oncology and targeted therapy areas financial guidance due to the COVID-19 impact settles Invitae, indicating that stock... Advice, and Genomic Health lower revenue than Invitae that have generated considerable revenue, per... The Guardant products for therapy selection are estimated to have a market opportunity in Lunar-1 be...